Inge Werter

DRS.

20192019

Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus

Werter, I. M., Huijts, C. M., Lougheed, S. M., Hamberg, P., Polee, M. B., Tascilar, M., Los, M., Haanen, J. B. A. G., Helgason, H. H., Verheul, H. M., de Gruijl, T. D., van der Vliet, H. J. & Dutch WIN-O Consortium, 1 May 2019, In : Cancer Immunology, Immunotherapy. 68

Research output: Contribution to journalArticleAcademicpeer-review

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma

Huijts, C. M., Werter, I. M., Lougheed, S. M., Goedegebuure, R. S., van Herpen, C. M., Hamberg, P., Tascilar, M., Haanen, J. B., Verheul, H. M., de Gruijl, T. D., van der Vliet, H. J. & Dutch WIN-O Consortium, Feb 2019, In : Cancer Immunology, Immunotherapy. 68, 2, p. 319-329

Research output: Contribution to journalArticleAcademicpeer-review

Open Access